UVA Protection Factors of SPF 50 and 50+ Face Sunscreens

Ultraviolet-Induced Change in Normal Skin Clinical Trial

Official title:

UVA Protection Factors of SPF 50 and 50+ Face Sunscreens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06068010
• Other study ID #: LRP20005-face sunscreens
• Status: Completed
• Start date: April 20, 2018
• Est. completion date: December 15, 2020

Study information

• Verified date: October 2023
• Source: Cosmetique Active International
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to use the International Organization for Standardization (ISO) 24442:2011 in vivo method for assessment of the Ultraviolet A Protection Factor (UVAPF) of topical sunscreen products in healthy adults. The main question it aims to answer is to determine the degree of UVA-protection against UVA radiation. An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure.

Description:

The objective of the study conducted in accordance with the Declaration of Helsinki and national regulations regarding human studies is to evaluate the UVA protection factor of the investigational products against UVA, according to the ISO 24442:2011 methodology comparatively to a standard product (Standard S2) in healthy adult subjects. Standard reference S2 sunscreen formula is used in a study if any test sample has an expected UVAPF of 12 or above. The mean UVAPF for the reference sample S2 is 12,7. The test result of the reference S2 UVAPF must be between 10,7 and 14,7 or the test is invalid and shall be repeated. The reference S2 may be used to validate any product test. In order to determine the number of subjects, the 95 % confidence interval (CI) shall be taken into account. The 95 % confidence interval should lie within ±17 % of the mean UVAPF, and a minimum of 10 subjects is required.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 412
• Est. completion date: December 15, 2020
• Est. primary completion date: December 15, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Fitzpatrick skin phototype: II, III or IV
• colorimetric Individual Typology Angle (ITA°): 20° to 41°
• intact skin on test site

Exclusion Criteria:

• pregnant or lactating women
• subjects using medication with photo-sensitizing potential
• subjects receiving chemotherapy or radiotherapy
• subjects who have had UV exposure on the back area in the four weeks prior to UVAPF testing

Related Conditions & MeSH terms

• Ultraviolet-Induced Change in Normal Skin

Locations

Country	Name	City	State
Brazil	Allergisa	Campinas
France	EVIC	Bordeaux
France	Intertek	Paris
France	Eurofins Dermscan France	Villeurbanne
Poland	Eurofins Dermscan Poland	Gdansk
Romania	CIDP	Bucharest

Sponsors (1)

Lead Sponsor	Collaborator
Cosmetique Active International

Countries where clinical trial is conducted

Brazil,  France,  Poland,  Romania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the protection factor of the investigational product against UVA	The UVAPF test method uses persistent pigment darkening (PPD) responses of the skin as the end point for evaluating transmitted UVA radiation. The test is restricted to the area of the back of selected human subjects. An area of each subject's skin is exposed to UVA light without any protection and another (different) area is exposed after application of the sunscreen product under test. One further area is exposed after application of a reference UVA sunscreen formulation (S2), which is used to validate the procedure.; To determine the UVAPF, incremental series of UVA exposures are delivered to five or six small sub-sites on the skin to induce darkening responses. These responses are visually assessed for pigment darkness 2 h to 24 h after UVA exposure, by the judgement of a trained evaluator.	from baseline to 24 hours